ATE443714T1 - Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen - Google Patents

Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Info

Publication number
ATE443714T1
ATE443714T1 AT02014617T AT02014617T ATE443714T1 AT E443714 T1 ATE443714 T1 AT E443714T1 AT 02014617 T AT02014617 T AT 02014617T AT 02014617 T AT02014617 T AT 02014617T AT E443714 T1 ATE443714 T1 AT E443714T1
Authority
AT
Austria
Prior art keywords
long
viral infections
peptide inhibitors
body cells
virus fusion
Prior art date
Application number
AT02014617T
Other languages
English (en)
Inventor
Dominique Bridon
Robert Dufresne
Nissab Boudjellab
Martin Robitaille
Peter Milner
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE443714(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE443714T1 publication Critical patent/ATE443714T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT02014617T 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen ATE443714T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10

Publications (1)

Publication Number Publication Date
ATE443714T1 true ATE443714T1 (de) 2009-10-15

Family

ID=26832297

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00932570T ATE226593T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
AT02014617T ATE443714T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00932570T ATE226593T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Country Status (13)

Country Link
US (4) US7582301B1 (de)
EP (3) EP1179012B2 (de)
JP (3) JP4216480B2 (de)
CN (1) CN1351611A (de)
AT (2) ATE226593T1 (de)
AU (1) AU761591B2 (de)
BR (1) BR0010757A (de)
CA (1) CA2372338A1 (de)
DE (2) DE60043021D1 (de)
DK (1) DK1264840T3 (de)
ES (2) ES2334106T3 (de)
PT (1) PT1264840E (de)
WO (1) WO2000069902A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1179012B2 (de) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ATE295370T1 (de) 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
KR100614714B1 (ko) 2001-06-15 2006-08-21 에프. 호프만-라 로슈 아게 gp41 단편의 아세틸화
EP1542718B1 (de) * 2002-09-24 2015-11-11 Dong Xie Von peptiden abstammende fusions-inhibitoren gegen hiv infektionen
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
HRP20060362A2 (en) * 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
EP1747233A4 (de) * 2004-05-06 2007-04-25 Verbindungen gegen ein spezifisches virales ziel
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发(河北)有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2054086A1 (de) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG Konjugat aus einem antikörper gegen ccr5 und einem antifusogenen peptid
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
WO2009019314A1 (en) 2007-08-08 2009-02-12 Novozymes A/S Transferrin variants and conjugates
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
EP2493921B1 (de) 2009-10-30 2018-09-26 Albumedix Ltd Albuminvarianten
EP2556087A1 (de) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albuminderivate und varianten
MX2013002556A (es) 2010-09-14 2013-05-28 Hoffmann La Roche Polipeptido de fusion de dedo de serpina.
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
EP2780364A2 (de) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteine mit verbesserter halbwertzeit und anderen eigenschaften
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US20160033523A1 (en) 2013-02-16 2016-02-04 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
EP2981334A4 (de) * 2013-04-03 2016-11-23 Univ California Zusammensetzungen und verfahren zur hemmung der viralen aktivität
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EP3535585A1 (de) 2016-11-04 2019-09-11 Aarhus Universitet Identifizierung und behandlung von tumoren, die durch eine überexpression des neonatalen fc-rezeptors charakterisiert sind
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ, インコーポレイテッド 抗体分子-薬物コンジュゲートおよびその使用
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses
EP4442251A1 (de) 2023-04-05 2024-10-09 Albumedix Ltd Formulierungen und verwendungen davon

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
KR100358209B1 (ko) 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
EP0867190B1 (de) 1995-05-10 2007-12-26 Kyowa Hakko Kogyo Co., Ltd. Cytotoxinkonjugate umfassend dipeptide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
AU1519699A (en) 1997-11-07 1999-05-31 Conjuchem, Inc. Affinity markers for human serum albumin
ATE235513T1 (de) * 1997-11-07 2003-04-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6818611B1 (en) * 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1179012B2 (de) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
ATE295370T1 (de) 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
HRP20060362A2 (en) * 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
EP1747233A4 (de) 2004-05-06 2007-04-25 Verbindungen gegen ein spezifisches virales ziel

Also Published As

Publication number Publication date
EP1264840B1 (de) 2009-09-23
US20080176794A1 (en) 2008-07-24
EP1179012B1 (de) 2002-10-23
BR0010757A (pt) 2002-02-19
DE60000665D1 (de) 2002-11-28
JP2002544287A (ja) 2002-12-24
ES2185595T5 (es) 2009-12-17
HK1053128A1 (en) 2003-10-10
WO2000069902A1 (en) 2000-11-23
JP4216480B2 (ja) 2009-01-28
JP2009167208A (ja) 2009-07-30
CA2372338A1 (en) 2000-11-23
EP1179012B2 (de) 2009-07-15
DE60000665T2 (de) 2003-06-26
JP2008101021A (ja) 2008-05-01
EP1264840A1 (de) 2002-12-11
EP2110381A1 (de) 2009-10-21
PT1264840E (pt) 2010-01-04
DE60000665T3 (de) 2009-10-29
ATE226593T1 (de) 2002-11-15
CN1351611A (zh) 2002-05-29
ES2185595T3 (es) 2003-05-01
DE60043021D1 (de) 2009-11-05
EP1179012B9 (de) 2003-09-10
DK1264840T3 (da) 2009-11-16
ES2334106T3 (es) 2010-03-05
AU5027100A (en) 2000-12-05
US7582301B1 (en) 2009-09-01
US20080199483A1 (en) 2008-08-21
US7608271B2 (en) 2009-10-27
EP1179012A1 (de) 2002-02-13
US20050070475A1 (en) 2005-03-31
AU761591B2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
ATE443714T1 (de) Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
BR9812547A (pt) Proteìnas de fusão compreendendo proteìnas hiv-1 tat e/ou nef
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
FI933740A0 (fi) Peg-interferonkonjugat
PE72799A1 (es) Interferones polietilen glicol modificados
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
LU92175I2 (fr) Lixisénatide
DE60037450D1 (de) Funf-helix protein
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
NO20014857L (no) Makrocykliske peptider aktive mot Hepatitt C virus
ATE516820T1 (de) Pegyliertes interleukin 10
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DE602004019887D1 (de) Physiologisch wirksames polypeptidkonjugat mit verlängerter in vivo halbwertszeit
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
EP1185545A4 (de) Cd4-unabhängige hiv-umschlagsproteine als vaccine und therapeutica
TR200001961T2 (tr) Ifnar 2/IFN kompleksi.
NO983054L (no) Virale rekombinante pseudopartikler og anvendelse som vaksiner og som anti-tumormiddel
ATE109158T1 (de) Rubella-e1 und c peptide.
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
DE69513632D1 (de) Mikrogranulate enthaltend 5-nitroimidazolderivate
ATE347899T1 (de) Interferon nachahmende peptide und rekombinante proteine
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1264840

Country of ref document: EP